Intelgenx (IGXT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Intelgenx (IGXT)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioHero	8/8/2016 7:42:52 AM
	of 10

Great News released Friday after hour , now they have a lot of Cash for 3 years but they could be already profitable by next year . IntelGenx Announces Sale of Forfivo XL(R) Royalty for $6 Million....August 05, 2016 intelgenx.com The Drug Montelukast mentioned below in the article alone is worth multiple times the current market cap of laughable $46 Million .If everything goes well with the potential Blockbuster Drug then IGXT will be the next Billion Dollar Company .With the large Pipeline they have and the terrible brutally low Valuation this stock is a Lifetiime opportunity .GL [B]The wonder pill that could STOP your brain ageing: Common asthma drug may be a cure for Alzheimer's, claims study[/B] dailymail.co.uk IntelGenx to Initiate Phase 1 Trial of Montelukast intelgenx.com IntelGenx expects results from the phase 1 trial to be available in September 2016. Following the completion of the phase 1 results, the Company will begin preparation work to initiate a phase 2 study where patients will be enrolled. IntelGenx will be actively seeking a partnership or alliance opportunity to complete the remaining developmental work and commercialization of this product. "Montelukast is by far the most important and promising drug repurposing opportunity that the company has in its product pipeline," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "IntelGenx with Dr. Aigner, is taking a leadership position in this most serious unmet need affecting millions globally. The market for degenerative diseases of the brain is a multi-billion-dollar opportunity for the company. [B]We look forward to communicating the results from the phase 1 study and advancing montelukast forward to reach its full potential." [/B]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next